German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of the medication.
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
We ran a screener using Benzinga Pro to filter out three mega-cap stocks that are currently trading at attractive valuations.
Obesity In Children – US Parents Face Tough Time To Access Recommended Treatment, Though Novo Nordisk’s Drug Still Sees Strong Demand
U.S. parents face significant barriers to accessing intensive behavioral counseling for childhood obesity, with programs often unavailable, not covered by insurance, and requiring substantial time commitments.
Novo Nordisk Unusual Options Activity For June 13
Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:NVO). And…
JPMorgan’s $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: ‘They’re All The Rage’
JPMorgan's $500M venture capital fund dives into weight-loss craze, eyeing potential market upheaval in pharmaceuticals.
Biosplice Announced Collaboration with Novo Nordisk in Diabetes; Terms Not Disclosed
Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK kinases, has entered a collaboration with Novo
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark’s Most Valuable Brand: Report
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss drugs, Ozempic and Wegovy.
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be… Pets?
Could GLP-1 drugs for weight loss in pets be the next big thing? Success of Novo Nordisk and Eli Lilly in human market could pave the way.
Jim Cramer Sees Eli Lilly As More Than A ‘One-Trick Pony’ After FDA Advisors Back Its Alzheimer’s Drug: ‘It’s Ultimately Headed To A Trillion Dollar Valuation’
Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors.